Pregled bibliografske jedinice broj: 1244137
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg) // The American journal of gastroenterology, 116 (2021), 6; 1220-1229 doi:10.14309/ajg.0000000000001246 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1244137 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Adverse Event Profile During the Treatment of
Helicobacter pylori: A Real-World Experience of
22,000 Patients From the European Registry on H.
pylori Management (Hp-EuReg)
Autori
Nyssen, OP ; Perez-Aisa, A ; Tepes, B ; Castro- Fernandez, M ; Kupcinskas, J ; Jonaitis, L ; Bujanda, L ; Lucendo, A ; Jurecic, NB ; Perez-Lasala, J ; Shvets, O ; Fadeenko, G ; Huguet, JM ; Kikec, Z ; Bordin, D ; Voynovan, I ; Leja, M ; Machado, JC ; Areia, M ; Fernandez-Salazar, L ; Rodrigo, L ; Alekseenko, S ; Barrio, J ; Ortuno, J ; Perona, M ; Vologzhanina, L ; Romero, PM ; Zaytsev, O ; Rokkas, T ; Georgopoulos, S ; Pellicano, R ; Buzas, GM ; Modolell, I ; Rodriguez, BJG ; Simsek, I ; Simsek, C ; Lafuente, MR ; Ilchishina, T ; Camarero, JG ; Dominguez-Cajal, M ; Ntouli, V ; Dekhnich, NN ; Phull, P ; Nunez, O ; Lerang, F ; Venerito, M ; Heluwaert, F ; Tonkić, A ; Caldas, M ; Puig, I ; Megraud, F ; O'Morain, C ; Gisbert, JP
Kolaboracija
Hp-EuReg Investigators
Izvornik
The American journal of gastroenterology (0002-9270) 116
(2021), 6;
1220-1229
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
PROTON-PUMP INHIBITOR ; TRIPLE THERAPY ; CONCOMITANT THERAPY ; ERADICATION THERAPY ; METAANALYSIS ; INFECTION ; LEVOFLOXACIN ; EFFICACY ; FAILURE ; CLARITHROMYCIN
Sažetak
INTRODUCTION: The safety of Helicobacter pylori eradication treatments and to what extent adverse events (AEs) influence therapeutic compliance in clinical practice are hardly known. Our aim was to assess the frequency, type, intensity, and duration of AEs, and their impact on compliance, for the most frequently used treatments in the European Registry on Helicobacter pylori management. METHODS: Systematic prospective non interventional registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H. pylori infection in routine clinical practice. All prescribed eradication treatments and their corresponding safety profile were recorded. AEs were classified depending on the intensity of symptoms as mild/moderate/severe and as serious AEs. All data were subject to quality control. RESULTS: The different treatments prescribed to 22, 492 patients caused at least 1 AE in 23% of the cases ; the classic bismuth-based quadruple therapy was the worst tolerated (37% of AEs). Taste disturbance (7 %) , diarrhea (7 %) , nausea (6%), and abdominal pain (3%) were the most frequent AEs. The majority of AEs were mild (57%), 6% were severe, and only 0.08% were serious, with an average duration of 7 days. The treatment compliance rate was 97%. Only 1.3% of the patients discontinued treatment due to AEs. Longer treatment durations were significantly associated with a higher incidence of AEs in standard triple, concomitant, bismuth quadruple, and levofloxacin triple or quadruple therapies. DISCUSSION: Helicobacter pylori eradication treatment frequently induces AEs, although they are usually mild and of limited duration. Their appearance does not interfere significantly with treatment compliance.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE